ProKidney Corp. (PROK) Stock Price & Analysis
ProKidney Corp. (PROK) is trading at USD 1.4, down 2.45% today, as of October 23, 2026 at 16:24 UTC (US market open; quotes may be delayed), according to Nexqual market data.
PROK last closed at USD 1.43; today's session has ranged USD 1.37–1.44 on volume of 258,545 shares. Market capitalization is $556.86M, with a 52-week range of USD 1.3–3.48 (NCM). Source: Nexqual, retrieved October 23, 2026 at 16:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PROK.md
Key facts (PROK)
- Last four reported quarters (through Jun 30, 2026): revenue $818K, net income -$84.2M (-10288.4% margin), free cash flow -$160M (SEC filings).
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $1.1M; 1 not under a Rule 10b5-1 plan ($1.1M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.67 on a 1–5 scale) (6 analysts), mean target USD 6.9 (range 1–12).
- Total return with dividends: 1Y -56.3% vs S&P 500 +14.7%; 5Y -85.9% vs S&P 500 +77.5%.
- Next earnings: 2026-11-09, EPS estimate USD -0.14, revenue estimate $125K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PROK)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $0K | $0K | $76K | $893K | $818K |
| Operating income | -$55.1M | -$153M | -$152M | -$184M | -$165M | -$177M |
| Net income | -$55.1M | -$148M | -$35.5M | -$61.2M | -$69.0M | -$84.2M |
| EPS (diluted) | — | -$0.23 | — | — | — | — |
| Free cash flow | -$55.5M | -$78.9M | -$124M | -$156M | -$135M | -$160M |
| Operating margin | — | — | — | -241678.9% | -18477.8% | -21664.5% |
| Net margin | — | — | — | -80507.9% | -7725.2% | -10288.4% |
| Revenue growth | — | — | — | — | +1075.0% | — |
| Cash + short-term investments | $20.6M | $490M | $60.6M | $99.1M | $109M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PROK)
P/S 680.8x · FCF yield -28.68% · Earnings yield -15.11%
Insider sales (SEC Form 4, open-market, last ~7 months) (PROK)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-18…2026-08-20 | Pereira Brian Jg | Director | 757,164 | $1.1M | 100% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (PROK)
Consensus Hold (mean 2.67 on a 1–5 scale), 6 analysts; mean target USD 6.9 (low 1, high 12).
Total return (dividends reinvested) (PROK)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -56.3% | -85.9% |
| S&P 500 (SPY) | +14.7% | +77.5% |
| Per year | -56.3% | -32.5% |
| Volatility (annualized) | 72.0% | 128.2% |
| Max drawdown | -58.7% (Oct 2025→Aug 2026) | -95.4% (Jul 2023→Mar 2025) |
PROK suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Eli Lilly (LLY) | “We believe that our principal competitors include developers of SGLT2 inhibitors, including canagliflozin (marketed as Invokana® by companies including Janssen Pharmaceuticals, Inc.), dapagliflozin (marketed under the brand names Farxiga® and Forxiga® by companies including AstraZeneca plc and Bristol-Myers Squibb Company), and empagliflozin (marketed as Jardiance® by companies including Boehringer Ingelheim and E…” |
Quoted from the company's 10-K filed Mar 18, 2026.
PROK analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.14 | $-0.14 | +2.3% | $124,600 | 4 |
| Next quarter (ends Dec 2026) | $-0.14 | $-0.14 | +0.4% | $453,400 | 4 |
| Current fiscal year (ends Dec 2026) | $-0.58 | $-0.54 | +7.3% | $529,000 | 4 |
| Next fiscal year (ends Dec 2027) | $-0.61 | $-0.58 | +5.5% | $494,200 | 4 |
PROK options: expected move
Options price a move of about ±26.6% (±$0.38) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±6.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 313.4% | ±26.6% |
| Jan 15, 2027 | 84 | 185.0% | ±28.0% |
| Apr 16, 2027 | 175 | 150.9% | ±80.4% |
30-day implied volatility 103.8% vs 74.4% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 16:25 UTC)
| Price | USD 1.4 |
|---|---|
| Change | ▼ 2.45% (down) |
| Previous Close | USD 1.43 |
| Open | USD 1.43 |
| Day Range | USD 1.37 – 1.44 |
| 52-Week Range | USD 1.3 – 3.48 |
| Volume | 258,545 shares |
| Market Cap | $556.86M |
| Exchange | NCM |
Technical Analysis (PROK)
Nexqual's technical model rates PROK "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 16:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 34.91 (neutral) |
| vs SMA50 | Below (USD 1.66) |
| MACD | -0.08 (negative) |
Analyst Ratings (PROK)
Wall Street analysts rate PROK "Hold" based on 6 analysts, with a mean price target of USD 6.9 (range USD 1–12), per Nexqual as of October 23, 2026 at 16:25 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 6.9 |
| High Target | USD 12 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 4 / 1 / 1 |
Earnings (PROK)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $124,600 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.15 vs est -0.14 ▼ miss |
| 2026-03-31 | USD -0.14 vs est -0.14 ▼ miss |
| 2025-12-31 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.14 ▲ beat |
Source: Nexqual, October 23, 2026 at 16:25 UTC.
Financials & Fundamentals (PROK)
| Total Revenue | $818,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -32.10% |
| Gross Margin | +100.00% |
| Operating Margin | -32248.67% |
| Profit Margin | +0.00% |
| ROE | -58.96% |
| Debt / Equity | 0.02 |
| Current Ratio | 8.36 |
| Total Cash | $181.56M |
| Total Debt | $3.52M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$159.73M (-19527.4% of revenue) |
Source: Nexqual, October 23, 2026 at 16:25 UTC.
Financial Health Score (PROK)
Nexqual rates ProKidney Corp.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 16:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $182M cash vs $4M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$160M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -59%, ROA -35.7% |
Ownership (PROK)
| Insider Ownership | +46.45% |
|---|---|
| Institutional Ownership | +26.51% |
| Shares Outstanding | 208.93M |
| Float | 184.65M |
| Short % of Float | +15.31% |
Source: Nexqual, October 23, 2026 at 16:25 UTC.
Leadership (PROK)
ProKidney Corp. is led by Bruce Culleton, CEO & Director, per Nexqual as of October 23, 2026 at 16:25 UTC.
| CEO & Director | Bruce Culleton |
|---|---|
| Chief Financial Officer | James Coulston |
| Senior Vice President of Interventional Procedures | Joseph M. Stavas M.D., M.P.H. |
Major Backers & Investors (PROK)
Notable institutional backers of ProKidney Corp. include Montanova Capital LLC, Morgan Stanley, Bleichroeder LP, according to Nexqual as of October 23, 2026 at 16:25 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Montanova Capital LLC | 5.91% |
| Morgan Stanley | 4.72% |
| Bleichroeder LP | 0.96% |
| Artia Global Partners LP | 0.86% |
| Hennion & Walsh Asset Management, Inc. | 0.86% |
| Fidelity | 0.58% |
| Renaissance Technologies | 0.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.49% |
| Geode Capital | 1.14% |
| Vanguard Group | 0.56% |
Source: Nexqual, October 23, 2026 at 16:25 UTC.
From ProKidney Corp.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
- We may also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position.
- To cover our proprietary technologies, proprietary cell-based rilparencel product and related methods, such as methods of use, we have filed patent applications representing 21 patent families.
- Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure to the preservation of kidney function.
Legal & Regulatory Risks (Item 1A, quoted)
- Our relationships with customers, health care providers, physicians, prescribers, purchasers, third-party payors, charitable organizations and patients will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- The FDA or a comparable foreign regulatory authority may also impose requirements for costly post-marketing nonclinical studies or clinical trials (often called Phase 4 trials) and post-marketing surveillance to monitor the safety or efficacy of the product.
- The FDA's policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of rilparencel or any of our future product candidates.
- Changes in health care policies, laws and regulations, including legislative measures aimed at reducing health care costs, may impact our ability to obtain approval for, or commercialize rilparencel or any of our future product candidates, if approved.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 312 | ▲ 1.36% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.95 | ▼ 1.05% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.04 | ▼ 0.71% |
| PRAX | Praxis Precision Medicines, Inc | USD 254.45 | ▼ 1.73% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.11 | ▼ 1.82% |
| ABVX | Abivax SA | USD 87.99 | ▼ 2.48% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt